FY2025 EPS Estimates for Indivior Cut by Northland Capmk

Indivior PLC (NASDAQ:INDV) – Equities researchers at Northland Capmk dropped their FY2025 EPS estimates for shares of Indivior in a research note issued on Thursday, February 20th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of $0.90 for the year, down from their prior estimate of $1.00. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

Several other research firms have also recently weighed in on INDV. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of Indivior in a report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target for the company.

Indivior Stock Up 0.1 %

Shares of NASDAQ:INDV opened at $8.26 on Monday. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -23.60 and a beta of 0.73. The business has a 50 day moving average price of $11.37 and a 200 day moving average price of $10.77. Indivior has a twelve month low of $7.33 and a twelve month high of $23.22.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.32. The company had revenue of $298.00 million during the quarter, compared to analysts’ expectations of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%.

Hedge Funds Weigh In On Indivior

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Indivior during the 4th quarter worth approximately $36,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Indivior in the fourth quarter worth $56,000. Lazard Asset Management LLC acquired a new stake in Indivior during the fourth quarter worth $57,000. Stifel Financial Corp bought a new stake in Indivior in the 3rd quarter valued at $100,000. Finally, Melqart Asset Management UK Ltd acquired a new position in shares of Indivior in the 3rd quarter valued at $132,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.